Project Start
1990-02-01
Project End
1995-01-31
Budget Start
1991-10-22
Budget End
1991-10-31
Support Year
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Saint Louis University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Saint Louis
State
MO
Country
United States
Zip Code
63103
Gorse, G J; Corey, L; Patel, G B et al. (1999) HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses 15:115-32
Gorse, G J; Patel, G B; Mandava, M et al. (1999) MN and IIIB recombinant glycoprotein 120 vaccine-induced binding antibodies to native envelope glycoprotein of human immunodeficiency virus type 1 primary isolates. National Institute of Allergy and Infectious Disease Aids Vaccine Evaluation Group. AIDS Res Hum Retroviruses 15:921-30
Gorse, G J; McElrath, M J; Matthews, T J et al. (1998) Modulation of immunologic responses to HIV-1MN recombinant gp160 vaccine by dose and schedule of administration. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. Vaccine 16:493-506
Gorse, G J; Patel, G B; Newman, F K et al. (1996) Antibody to native human immunodeficiency virus type 1 envelope glycoproteins induced by IIIB and MN recombinant gp120 vaccines. The NIAID AIDS Vaccine Evaluation Group. Clin Diagn Lab Immunol 3:378-86
Gorse, G J; Yang, E Y; Belshe, R B et al. (1996) Salivary binding antibodies induced by human immunodeficiency virus type 1 recombinant gp120 vaccine. The NIAID AIDS Vaccine Evaluation Group. Clin Diagn Lab Immunol 3:769-73
Gorse, G J; Rogers, J H; Perry, J E et al. (1995) HIV-1 recombinant gp160 vaccine induced antibodies in serum and saliva. The NIAID AIDS Vaccine Clinical Trials Network. Vaccine 13:209-14
Schwartz, D H; Mazumdar, A; Winston, S et al. (1995) Utility of various commercially available human immunodeficiency virus (HIV) antibody diagnostic kits for use in conjunction with efficacy trials of HIV-1 vaccines. Clin Diagn Lab Immunol 2:268-71
Gorse, G J; Patel, G B; Newman, F K et al. (1995) Recombinant gp160 vaccination schedule and MHC HLA type as factors influencing cellular responses to HIV-1 envelope glycoprotein. NIAID AIDS Vaccine Clinical Trials Network. Vaccine 13:1170-9
Belshe, R B; Clements, M L; Keefer, M C et al. (1994) Interpreting HIV serodiagnostic test results in the 1990s: social risks of HIV vaccine studies in uninfected volunteers. NIAID AIDS Vaccine Clinical Trials Group. Ann Intern Med 121:584-9
Keefer, M C; Graham, B S; Belshe, R B et al. (1994) Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials Network. AIDS Res Hum Retroviruses 10:1713-23

Showing the most recent 10 out of 15 publications